NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by American Century Companies Inc.

American Century Companies Inc. decreased its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 4.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,893,261 shares of the medical research company's stock after selling 132,683 shares during the period. American Century Companies Inc. owned approximately 2.25% of NeoGenomics worth $47,681,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Natixis Advisors LLC grew its position in NeoGenomics by 54.1% in the third quarter. Natixis Advisors LLC now owns 33,982 shares of the medical research company's stock worth $501,000 after acquiring an additional 11,936 shares during the period. Intech Investment Management LLC raised its stake in shares of NeoGenomics by 55.1% in the third quarter. Intech Investment Management LLC now owns 46,984 shares of the medical research company's stock valued at $693,000 after acquiring an additional 16,684 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of NeoGenomics by 5.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,134,651 shares of the medical research company's stock worth $16,736,000 after buying an additional 57,677 shares during the period. Algert Global LLC lifted its position in shares of NeoGenomics by 204.3% during the 3rd quarter. Algert Global LLC now owns 79,983 shares of the medical research company's stock worth $1,180,000 after purchasing an additional 53,700 shares during the last quarter. Finally, Loomis Sayles & Co. L P acquired a new position in shares of NeoGenomics during the 3rd quarter worth about $17,807,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

NEO has been the subject of several research analyst reports. The Goldman Sachs Group lowered their target price on shares of NeoGenomics from $20.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. Benchmark downgraded shares of NeoGenomics from a "buy" rating to a "hold" rating in a research note on Monday, January 13th. Jefferies Financial Group started coverage on NeoGenomics in a research report on Tuesday, December 10th. They set a "buy" rating and a $22.00 target price on the stock. Needham & Company LLC decreased their target price on NeoGenomics from $19.00 to $18.00 and set a "buy" rating for the company in a research report on Wednesday, February 19th. Finally, Piper Sandler dropped their price target on NeoGenomics from $21.00 to $18.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, NeoGenomics currently has a consensus rating of "Moderate Buy" and a consensus target price of $19.60.

NeoGenomics Stock Performance

NEO traded up $0.14 on Friday, hitting $9.62. 1,995,897 shares of the company traded hands, compared to its average volume of 880,633. NeoGenomics, Inc. has a 12-month low of $8.98 and a 12-month high of $19.12. The company has a 50 day moving average of $11.92 and a 200-day moving average of $14.34. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $1.24 billion, a PE ratio of -15.52 and a beta of 1.28.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The company had revenue of $172.00 million for the quarter, compared to analysts' expectations of $173.40 million. Sell-side analysts anticipate that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.